摘要
目的：探讨多药耐药相关蛋白（multidrug resistance-associated protein，MRP）在鼻咽癌中的表达及与临床分期的关系。方法：对73例鼻咽癌采用免疫组化SP法检测鼻咽癌中MRP的表达，并分析其表达与临床分期的关系。结果：鼻咽癌中有较高水平的MRP表达，阳性表达率为68．49％（50／73）。其中，MRP在Ⅰ～Ⅱ期的阳性表达率为58．33％（7／12），Ⅲ～Ⅳ期的阳性表达率为70．49％（43／61）；T1～2期的阳性表达率为61．54％（24／39），T3～4期中阳性表达率为76．47％（26／34）；N0～1期的阳性表达率为69．70％（23／33），N2～3期中阳性表达率为67．50％（27／40）。以上表达率经检验差异无统计学意义，P〉0．05。结论：MRP基因在鼻咽癌中有较高的表达水平，但其表达与临床分期无关。
OBJECTIVE： To evaluate the relationship between the clinical stages of nasopharyngeal carcinoma （NPC） and the expression of multidrug resistance-associated protein （MRP）. METHODS：Total 73 cases of NPC were analyzed by using the immunohistochemical SP method. The expression of MRP in NPC was detected, and the relationship between the clinical stages and the expression of MRP was analyzed. RESULTS：There was higher expression of MRP in NPC and the rate of positive expression was 68.49%（50/73）. The rates of positive expression of MRP were 58.33% and 70.49% （7/12, 43/61, respectively）in Ⅰ--Ⅱ stages and Ⅲ--Ⅳ stages respectively, and 61.54 % and 76.47 % （24/39, 26/34, respectively） in T1-2 and T3-4 respectively, and 69.70% and 67.50% （23/33, 27/40, respectively）in N0-1 and N2-3 stages respectively. The rates of expression of MRP among them above meatimed had no significant differences tested by Chi square, P〈0.05. CONCLUSIONS： There is higher expression of MRP in NPC, but the expression of MRP to the clinical stage of NPC.
出处
《中华肿瘤防治杂志》
CAS
2006年第6期433-434,共2页
Chinese Journal of Cancer Prevention and Treatment
关键词
鼻咽肿瘤/病理学
抗药性
多药
免疫组织化学
预后
nasopharyngeal neoplasms/pathology
drug resistance,multidrug
immunohistochemistry
prognosis
